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miR-25 Targets TRAIL Death Receptor-4 and Promotes
Apoptosis Resistance in Cholangiocarcinoma
Nataliya Razumilava, Steve F. Bronk, Rory L. Smoot, Christian D. Fingas, Nathan W.
Werneburg, Lewis R. Roberts, and Justin L. Mott
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN,
55905, USA.

Abstract

NIH-PA Author Manuscript

It has been established that microRNA expression and function contribute to phenotypic features
of malignant cells, including resistance to apoptosis. While targets and functional roles for a
number of microRNAs have been described in cholangiocarcinoma, many additional microRNAs
dysregulated in this tumor have not been assigned functional roles. In this study, we identify
elevated miR-25 expression in malignant cholangiocarcinoma cell lines as well as patient samples.
In cultured cells, treatment with the Smoothened inhibitor, cyclopamine, reduced miR-25
expression, suggesting Hedgehog signaling stimulates miR-25 production. Functionally, miR-25
was shown to protect cells against TNF-Related Apoptosis-Inducing Ligand (TRAIL)-induced
apoptosis. Correspondingly, antagonism of miR-25 in culture sensitized cells to apoptotic death.
Computational analysis identified the TRAIL Death Receptor-4 (DR4) as a potential novel
miR-25 target, and this prediction was confirmed by immunoblot, cell staining, and reporter
assays.
Conclusion—These data implicate elevated miR-25 levels in the control of tumor cell apoptosis
in cholangiocarcinoma. The identification of the novel miR-25 target DR4 provides a mechanism
by which miR-25 contributes to evasion of TRIAL-induced cholangiocarcinoma apoptosis.
MicroRNA expression is altered in a variety of human cancers, with some microRNAs
exhibiting increased expression levels and others reduced amounts compared to non tumor
samples (1). Functionally, microRNAs contribute to many processes, including oncogenesis,
angiogenesis, cell death, and metastasis. Thus, the control of microRNA levels in cancer
cells, as well as their particular protein targets, is an active area of investigation.
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Among the microRNAs known to be dysregulated in disease states, miR-25 is expressed at
altered levels in a number of cancers. miR-25 is 22 nucleotides in length, hosted by the
minichromosome maintenance protein-7 (MCM7) gene, and transcribed as part of the
mir-106b~25 polycistron. Examples of miR-25 dysregulation include its upregulation in
pediatric brain tumors of multiple histological classifications (2), prostate carcinoma (3),
gastric adenocarcinoma (4), and epidermal growth factor receptor-positive lung
adenocarcinoma (5). In the liver, miR-25 is elevated in hepatocellular carcinoma cell lines
(6, 7) and human hepatocellular carcinoma samples (8, 9), and was among the microRNAs
shown to be overexpressed in intrahepatic cholangiocarcinoma (10). Further, exposure to
tamoxifen, a known inducer of liver cancer, increased hepatic miR-25 expression in rats
(11). Notably, elevated miR-25 levels are not universally associated with a worse disease
course, for instance in acute myelogenous leukemia (12). Therefore, the particular functional
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effect of elevated microRNA quantities cannot necessarily be generalized from one tumor
type to another.
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Cholangiocarcinoma represents the second most common primary hepatobiliary cancer (13)
and is resistant to apoptosis mediated by TRAIL, a major player in the extrinsic death
pathway (14). Similar to other tumors, cholangiocarcinoma paradoxically expresses TRAIL
(15-17) and, therefore, may rely on strong cellular survival signals for tumor development.
We report a role for miR-25 in regulating apoptotic signaling in cholangiocarcinoma cell
lines and human tumor samples. Increased miR-25 repressed Death Receptor-4 (DR4)
protein expression protecting cells from TRAIL-induced death, and this effect was reversed
on antagonism of miR-25.

MATERIALS and METHODS
Human Tissue Samples
All protocols involving patient materials were approved by the institutional review board,
Mayo Clinic, Rochester MN. Cholangiocarcinoma samples from 15 patients and benign
adjacent tissue from 4 patients were obtained intraoperatively and preserved according to a
frozen tissue storage protocol. All samples were reviewed by a pathologist to verify the
presence of malignant transformation.
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Cell Culture
H69 is a non-malignant SV40-immortalized human cholangiocyte cell line, cultured as
described (18). Malignant, patient-derived cholangiocarcinoma cell lines were: KMCH cells,
derived from intrahepatic cholangiocellular-hepatocellular carcinoma, and Mz-ChA-1 cells,
derived from metastatic gallbladder cancer. These were cultured in DMEM supplemented
with 10% (v/v) heat-inactivated fetal calf serum, penicillin, streptomycin, and geneticin.
Manipulation of microRNA Levels
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Consistent with current nomenclature (19), we refer to the mature sequences as ‘miR’ (as in
miR-25; note capitalization), whereas clustered microRNAs, genes, and precursors are
labelled ‘mir’ (as in mir-106b~25). pCDNA-mir-25 was constructed by amplification of 184
base pairs of human miR-25 and nearby sequence using the following primers: forward 5 'TCTGGTCTCCCTCACAGGAC; reverse 5'-CATGGGTCGCCTACTCAC. After TOPO
TA cloning (Invitrogen, Carlsbad, CA, USA), the SpeI/EcoRV fragment was subcloned into
the XbaI/EcoRV sites of pCDNA3.1(+). In vitro transcription was performed (T7, Mega
Script; Ambion, Austin, TX, USA) on linearized pCDNA-mir-25 or empty pCDNA3.1(+) as
control. Antisense locked nucleic acids (LNA) were targeted to miR-25 or miR-106b, and
compared to Negative Control A LNA (Exiqon, Vedbaek, Denmark). Cell lines were
transiently transfected with microRNA precursor (final concentration, 7.5 nM) or antagonist
(final concentration, 20 nM) with FuGENE HD (Promega, Madison, WI, USA) and
Lipofectamine 2000 (Invitrogen) reagents, respectively. Total RNA was isolated 24
(precursor), or 48 hours (LNA) after transfection.
Quantitative Reverse Transcription Polymerase Chain Reaction
Total RNA was isolated using the mirVana kit (Ambion; for microRNA) or by Trizol
(mRNA). MicroRNA was quantified by reverse transcription polymerase chain reaction
(qRT-PCR; Applied Biosystems, Foster City, CA, USA). Profiling of 95 microRNAs plus
RNU-6B was performed using Sybr Green detection and miScript primer assays (Qiagen,
Valencia, CA, USA). mRNA quantitation was conducted utilizing Sybr Green-based
detection technology (Roche Applied Science, Mannheim Germany). Primers for DR4 (20),
and 18S (21) have been described and for MCM7 were: forward 5'Hepatology. Author manuscript; available in PMC 2013 February 1.
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TCTGGACATGAAGCTCATG; reverse 5'-GTAGTCAGCCAGAGACTCTG. For mRNA
degradation studies, cells were treated for 0-6 hours with actinomycin D (5 ȝg/mL; Sigma)
followed by DR4 mRNA and 18S rRNA quantitation by qRT-PCR.
Apoptosis Studies
Recombinant human TRAIL from R&D Systems (375-TEC; Minneapolis, MN, USA) was
used (1-5 ng/mL) to initiate apoptosis. Cells were analyzed via fluorescence microscopy for
apoptotic nuclear morphology (condensation and fragmentation) after staining with 4'-6diamidino-2-phenylindole (DAPI; Sigma, St. Louis, MO, USA). For apoptosis studies in
cells transfected with miR-25-resistant DR4, green fluorescent protein (GFP)-tagged DR4
(DR4-GFP)(22) was co-transfected with pCDNA-mir-25. Control studies included the GFPN1 empty vector (Clontech, Mountain View, CA, USA). Only GFP-positive cells were
scored for apoptotic nuclear morphology.
Immunoblotting
Whole cell lysates were obtained and processed for immunoblotting as described in detail
previously (23). Primary antisera were: Death Receptor-4 (DR4; Alexis, San Diego, CA,
USA), DR5 and c-FLIP (ProSci, Poway, CA, USA), Bim and caspase-8 (BD Biosciences,
San Jose, CA, USA), Mcl-1 and actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA:
S19 for Mcl-1 and C-11 for actin).

NIH-PA Author Manuscript

Immunofluorescence
Cells cultured on collagen-coated glass coverslips were transfected and prepared for
immunofluorescence analysis according to the protocol of Xu, et al. (24). Cells were
incubated overnight with 1:1000 anti-DR4 (10 ȝg/mL) or anti-DR5 (5 ȝg/mL) antisera
(ProSci), as indicated. Alexa Fluor® 488-labeled goat anti-rabbit IgG (Invitrogen), was
diluted 1:2000 in blocking buffer. Cells were post-stained with DAPI and examined with
confocal microscopy (LSM 510, Carl Zeiss, Jena, Germany), and images were analyzed
using ImageJ (NIH, Bethesda, MD, USA). At least 23 cells were included in the analysis for
each condition.
Luciferase Reporter Assay
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MicroCosm (25) was used to predict the miR-25 binding site within DR4. The DR4 3'UTR
was amplified from human genomic DNA using the following primers: forward 5'GTCCTTGGAGTGAAAGACTC; reverse 5'-GTAAAGACGGCATTTCACGATG. The
226 base-pair product was cloned (TOPO TA) and the SpeI/EcoRV fragment subcloned into
the SpeI/NaeI sites of pMir-REPORT (Ambion). The resultant pMirDR4 was mutated by
PCR using primers designed to incorporate a 2-base substitution into the miR-25 binding
site (5'-CAGGTGTAGTGG converted to 5'-CAGGTGTccTGG). The resulting pMirDR4
constructs were cotransfected with pRL-CMV (Promega). Twenty-four hours after
transfection, firefly and Renilla luciferase activities were analyzed using the Dual-Luciferase
Reporter Assay System (Promega). Protein content in lysates was measured using the
Bradford method.
Statistical Analysis
At least three replicates were obtained for each condition in experiments with cell cultures.
For quantitative continuous data differences between two groups, data were analyzed by
Student's t-test with a threshold for significance defined at p<0.05. When multiple
comparisons were possible, ANOVA coupled with Bonferroni post hoc correction was used.
For microRNA miScript evaluation, significance analysis of microarray (SAM) was applied.
All data are presented as mean +/- standard error of the mean (SEM).
Hepatology. Author manuscript; available in PMC 2013 February 1.
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RESULTS
Hedgehog Signaling is Involved in Regulation of mir-106b~25 Expression
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Activation of the Hedgehog signaling pathway is a recently appreciated feature of human
cholangiocarcinoma (20, 26), with the potential to regulate microRNA expression (27). We
sought to identify additional microRNAs that may be under control of Hedgehog signaling
by profiling microRNA expression from KMCH cells that were untreated (vehicle), treated
with the Smoothened inhibitor cyclopamine (5 ȝM), or treated with Sonic Hedgehog ligand
(500 nM). Of the 95 microRNAs assayed, we determined that 14 microRNAs were
downregulated upon Hedgehog inhibition (Table 1, and Supplemental Fig. 1). Of the
cyclopamine-responsive microRNAs, miR-15b, miR-25, and miR-125a-5p were detected at
the highest relative expression levels. Cyclopamine treatment decreased miR-15b expression
by 52%, miR-25 by 76%, and miR-125a-5p by 51%.
We selected miR-25 for further analysis based on the magnitude of its repression upon
cyclopamine treatment and its importance in tumor biology. Interestingly, miR-106b, which
is part of the mir-106b~25 polycistron and located less than 600 bases from miR-25, was
also significantly repressed by cyclopamine (Table 1). While miR-93, the third member of
the mir-106b~25 cluster at this locus, was not identified by the statistical approach, a similar
expression pattern of all three microRNAs is apparent (Fig. 1).
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mir-106b~25 is Overexpressed in Cholangiocarcinoma
We next conducted studies to investigate if mir-106b~25 indeed is involved in
cholangiocarcinoma biology. We first employed benign cholangiocytes (H69) and malignant
cholangiocarcinoma (Mz-ChA-1, KMCH) cell lines. Quantitation of miR-106b, miR-93, and
miR-25 expression demonstrated overexpression of all three microRNAs in
cholangiocarcinoma cell lines compared with benign cells (Fig. 2A-C). Among 15 human
primary cholangiocarcinoma tumor samples, 9 demonstrated an increase in miR-106b
expression (Fig. 2D), a slight increase of miR-93 expression was demonstrated in four
samples (Fig. 2E), and 6 samples exhibited increased miR-25 expression (Fig. 2F).
Approximately 27% of human samples (4 of 15) had a concurrent increase of all three
cluster members. Thus, mir-106b~25 expression is upregulated in malignant
cholangiocarcinoma cell lines and a subset of primary cholangiocarcinomas.
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To determine if increased expression of this cluster was due to elevated host gene RNA
levels, we measured MCM7 mRNA in H69, KMCH, and Mz-ChA-1 cells. There was
significantly more MCM7 in KMCH compared to H69 cells, while Mz-ChA-1 cells
expressed similar amounts to H69 (Fig. 3A). In the primary human tumor samples, we
analyzed 10 samples for MCM7 mRNA levels, divided equally as 5 samples that had
increased miR-25 levels (#69, 75, 29, 65, and 87) and 5 with low miR-25 levels (#85, 63,
73, 49, and 39). The amount of MCM7 in the tumor samples that had high miR-25 was
nearly 3-fold higher than those with low miR-25 (Fig. 3B). These data seem to indicate that
increased host gene expression may explain, at least in part, the elevation of these
microRNAs.
TRAIL-mediated Apoptosis is Attenuated by miR-25
To define the effect of miR-25 on apoptosis, we first employed the non-malignant H69 cells
that had relatively lower miR-25 expression. Enforced expression of miR-25 protected these
cells from TRAIL-induced apoptosis by >40% compared to control RNA (Fig. 4A). Next,
we investigated the effect of miR-25 antagonism in KMCH cells, which normally express
miR-25 at elevated levels. Upon antagonism of miR-25 with LNA-25, KMCH cells
demonstrated at least a 25% increase in apoptosis compared to control-transfected cells (Fig.
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4B). Therefore, we demonstrated that increased miR-25 protected, and, conversely,
decreased miR-25 sensitized cholangiocarcinoma cell lines to TRAIL-induced apoptosis.
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miR-25 Suppresses TRAIL Death Receptor
TRAIL Death Receptors DR4 and DR5, caspase-8, cellular FADD-like interleukin-1ȕ –
converting enzyme-inhibitory protein (c-FLIP), Mcl-1, and Bim all participate in the cell
death pathway triggered in cholangiocarcinoma by TRAIL. Moreover, DR4, Bim, and Mcl-1
were identified by computational analysis as predicted targets for miR-25. We sought to
identify the functional miR-25 targets that influence TRAIL signaling in
cholangiocarcinoma. Quantitation of miR-25 expression after transfection with mir-25
precursor confirmed the overexpression paradigm (Fig. 5A). Similarly, antagonism of
endogenous miR-25 was demonstrated in KMCH cells transfected with LNA targeting
miR-25 (LNA-25; Fig. 5B). Cellular DR4, but not DR5, Bim, Mcl-1, Caspase-8, or c-FLIP
protein expression was efficiently reduced by miR-25 overexpression in KMCH cells (Fig
5C). Because DR4 is a novel miR-25 target, we verified this interaction in H69 and MzChA-1 cells (Fig. 5D). Conversely, antagonism of miR-25 caused increased DR4 protein
expression in KMCH cells. Specificity of LNA-25 was confirmed by transfection of the
miR-106b antagonist (LNA-106), which had no effect on DR4 protein levels (Fig. 5E). DR4
protein in each of these cell lines was readily detected, and found to be more abundant in
Mz-ChA-1 cells (Fig. 5F).
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Antagonism of miR-25 also increased DR4 protein levels when examined by
immunofluorescence staining of KMCH cells. Specifically, cells transfected with LNA-25
demonstrated a significant increase in the intensity of DR4 immunostaining, an effect not
seen for DR5 (Fig. 6A). Quantitation of the fluorescent signal revealed a greater than twofold increase in DR4 immunoreactivity in LNA-25 transfected cells versus control LNA
(CT; Fig. 6B). Conversely, upregulation of miR-25 in H69 cells resulted in significantly
decreased DR4 immunoreactivity (Fig. 6C, 6D). This decrease is consistent with
immunoblot data in H69 cells (Fig. 5D). These findings confirmed that DR4 is a target
protein for regulation of the TRAIL-induced death pathway by miR-25.
Enforced DR4 Expression Restored TRAIL Sensitivity
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H69 cells transfected with a miR-25 expression vector (pCDNA-mir-25) demonstrated
resistance to TRAIL-induced apoptosis, as anticipated and consistent with Figure 4A above.
Importantly, a DR4 expression plasmid that lacked the DR4 3'UTR (and thus lacked the
putative miR-25 binding site) lead to restoration of sensitivity to TRAIL-induced apoptosis
in TRAIL treated cells (Fig. 6E). The effect of miR-25 to repress DR4 protein levels and
protect cells from TRAIL-induced apoptosis is consistent with previous findings that DR4 is
important in cholangiocarcinoma cells. Short-hairpin RNA against DR4 protected KMCH
cells from TRAIL-induced apoptosis, while transient transfection with a DR4-expression
vector sensitized these cells to TRAIL (20).
Direct Targeting of DR4 3'UTR by miR-25
A proposed mechanism of microRNA regulation of protein expression is via binding of the
microRNA to a region within a cognate mRNA, resulting in repression by either mRNA
degradation or translational inhibition. The steady-state amount of DR4 mRNA in H69,
KMCH, and Mz-ChA-1 cells did not indicate that cell lines with elevated miR-25 (KMCH
and MzChA-1) had depressed DR4 mRNA levels (Fig. 7A). To further assess a potential
inverse correlation, we measured DR4 mRNA in patient-derived cholangiocarcinoma
samples stratified into high (n = 5) or low (n = 5) miR-25. Again, elevated miR-25 was not
strictly correlated with low DR4 mRNA (Fig. 7B). Finally, increased miR-25 expression did
not accelerate DR4 mRNA degradation compared to control. Six hours after the addition of
Hepatology. Author manuscript; available in PMC 2013 February 1.
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the transcriptional inhibitor actinomycin D, miR-25 transfected H69 cells expressed 73.2%
of DR4 compared to time zero, while control cells expressed 44.1% (data not shown).
Conversely, KMCH cells transfected with the miR-25 antagonist, LNA-25, showed only a
slight increase in DR4 mRNA stability, with DR4 levels of 13.7% of time zero and control
LNA-transfected cells had 7.1% of DR4 after 6 hours of actinomycin treatment (now
shown). Collectively, we interpret these data to support repression of DR4 protein
expression through translational inhibition, rather than mRNA degradation.
To determine if the repression of DR4 is the result of direct binding to the DR4 3'UTR, we
used a luciferase reporter assay employing the empty reporter (pMir), the reporter fused to
the full-length DR4 3'UTR (pMirDR4), or the DR4 reporter with a two-base mutation at the
miR-25 binding site (pMirDR4-25mut; Fig. 7C). Compared to the parental vector, pMirDR4
exhibited inhibition of luciferase expression upon enforced miR-25 expression. Mutation of
the miR-25 binding site partially mitigated repression (Fig. 7D). Therefore, our data are
consistent with the hypothesis that miR-25 repressed DR4 protein levels via direct targeting
of the 3'UTR of DR4.

DISCUSSION
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We and others have begun to define the altered microRNA landscape in cholangiocarcinoma
(28-32). The main findings of this project identified an important molecular mechanism of
apoptosis regulation by the oncogenic miR-25. First, our study demonstrated that members
of the mir-106b~25 cluster are upregulated in cholangiocarcinoma cell lines, KMCH and
Mz-ChA-1, and a subset of human tumors. Second, we provided evidence that miR-25
serves as an antiapoptotic microRNA in these cells, protecting against TRAIL-induced
apoptosis. Finally, we have identified a novel target of miR-25 in the extrinsic pathway of
cell death, namely DR4. Antagonism of miR-25 caused increased DR4 protein expression
and sensitized cells to apoptosis. Combined, these data support a functional role for elevated
miR-25 expression in apoptosis regulation of cholangiocarcinoma. Each of these findings
will be discussed below.
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MicroRNA gene sequences are often located in clusters where multiple precursor sequences
can be transcribed on the same primary transcript. A substantial portion of microRNA
coding sequences lie within a host gene, commonly in an intron. For miR-25, both of these
situations apply, as mir-106b~25 is in an intron of MCM7, located at the fragile site FRA7F
on chromosome 7. Our data demonstrate increased expression of all three microRNAs from
this locus in cholangiocarcinoma cells and some tumor samples. It is anticipated that
transcription of this microRNA cluster is linked to that of the host gene, MCM7, as has been
shown in other cell types (33, 34). Indeed, the current investigation revealed that miR-25
RNA and MCM7 levels are correlated in H69 and KMCH (though not MzChA-1). Also, in
tumor samples with high miR-25, MCM7 was also elevated. These initial data may indicate
that miR-25 is co-transcribed with the MCM7 mRNA, however, additional contributions
from altered processing and degradation cannot be ruled out.
The fact that some, but not all, human cholangiocarcinoma samples had increased miR-25
expression may indicate that a particular genetic predisposition, tumor microenvironment, or
perhaps differences in underlying patho- or oncogenesis might determine miR-25
dysregulation. Hedgehog reactivation in cholangiocarcinoma and liver injury is emerging as
an important pathologic signal (35). Interestingly, in a subset of medulloblastomas
constitutive activation of Sonic Hedgehog was reported to be associated with overexpression
of the microRNA cluster mir-17~92, a paralog of mir-106b~25 (36). We present initial
findings consistent with stimulation of miR-106b, miR-93, and miR-25 by the oncogenic
Hedgehog pathway. Interestingly, we did not observe an increase in microRNA expression

Hepatology. Author manuscript; available in PMC 2013 February 1.
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upon treatment with the recombinant Sonic Hedgehog ligand, which may indicate preexisting pathway activation, for istance through autocrine expression of Hedgehog ligands
(20). It is anticipated that additional signals may be discovered that also increase miR-25
levels in cholangiocarcinoma, possibly including host gene stimulation (37). Future studies
may also investigate a potential link between clinical parameters (intrahepatic versus
extrahepatic; localized versus advanced) and miR-25 expression.
Consistent with reports of other tumor types, we found that miR-25 had an antiapoptotic role
in cholangiocarcinoma cells, specifically, by protecting from TRAIL-induced cell death.
This observation was reinforced by experiments with a miR-25 antagonist, LNA-25, which
lead to apoptosis stimulation in our study. Evasion of TRAIL-induced apoptosis would
presumably exempt tumor cells from immunologic surveillance. As previously described,
this death ligand is expressed in human cholangiocarcinoma samples, likely in response to
interferon-Ȗ within the tumor microenvironment (17). Thus, resistance to TRAIL-induced
apoptosis observed in cholangiocarcinoma cell lines may be necessary for the establishment
and maintenance of this cancer. Our data implicate a role for miR-25 overexpression in the
resistance to apoptosis.
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TRAIL apoptotic signaling in cholangiocarcinoma includes induction of the mitochondrial
pathway of apoptosis. Mitochondrial dysfunction can be initiated by the BH3-containing
protein Bim (38), and recently Bim was described as a target of miR-25 in esophageal
neoplasia (34). Thus, we initially considered that miR-25 likely exerted its protective effect
in cholangiocarcinoma cells through repression of Bim, thus decreasing the intracellular
apoptotic signal. Surprisingly, we did not find that miR-25 suppressed Bim protein levels or
that antagonism of miR-25 increased Bim expression in cholangiocarcinoma cells. We
conclude that microRNA function is likely cell-type specific, and may be regulated by as yet
unknown conditions.
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Because Bim protein levels were not reduced by miR-25 (nor induced by LNA-25), we
searched for alternate targets. The DR4 mRNA has a predicted miR-25 binding site within
the 3'UTR, and, indeed, experiments with miR-25 overexpression or inhibition induced
reciprocal effects on DR4 protein levels. The repression of DR4 was specific, in that
multiple other participants in the TRAIL death signaling pathway showed no change in
response to miR-25 manipulation. Additionally, immunofluorescence studies of DR4 and
DR5 demonstrated that only DR4 immunoreactivity was increased upon miR-25
antagonism. Finally, direct targeting of the DR4 3'UTR by miR-25 was identified by a
luciferase reporter assay. Luciferase experiments demonstrated that miR-25 repression of the
signal was dependent on the presence of the DR4 3'UTR, and mutation of the putative
miR-25 binding site lead to restoration of luciferase expression. We note that this restoration
may be partial, as careful inspection of the data reveals that the mutant construct displayed a
slight decrease in signal upon enforced miR-25 expression, though this effect was not
statistically significant. This observation might indicate the presence of additional, cryptic
miR-25 binding sites.
DR4 protein expression includes several layers of regulation, e.g. epigenetic silencing, lossof-function mutations, and dysregulation of cellular localization (39). Here we identified an
additional mechanism controlling DR4 protein levels in cholangiocarcinoma cells, namely
miR-25 repression of DR4. Possibly due to one or more of these alternative DR4 regulatory
pathways, the DR4 protein signal in untreated cell lines in vitro is not inversely correlated
with miR-25 expression. This lack of correlation cannot be taken as evidence that miR-25
does not regulate DR4, especially given the reciprocal effects of increased or decreased
miR-25 on DR4 protein expression. We demonstrated that cells can be resensitized to
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TRAIL-induced apoptosis upon restoration of DR4 protein in miR-25 transfected cells. It is
likely that resting amounts of DR4 protein are determined by multiple mechanisms.
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The finding that miR-25 targets DR4, coupled with the implication of Hedgehog as a
mediator of increased miR-25 levels (Fig. 8) is consistent with the observation that
Hedgehog inhibition both increased DR4 protein and sensitized to apoptosis (20). The
findings reported in the previous work also demonstrated direct transcriptional repression of
DR4, such that Hedgehog inhibition lead to increased DR4 mRNA. This current manuscript
builds on these observations, supporting a dynamic and complex inhibition of DR4
expression at the mRNA and protein levels.
In conclusion, overexpression of miR-25 in cholangiocarcinoma was observed to negatively
regulate apoptosis signaling and DR4 protein levels. Thus, this microRNA may serve as an
attractive candidate for suppression to facilitate increased tumor cell death during cytotoxic
therapy of this and other cancers.
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DAPI

4'-6-diamidino-2-phenylindole

DR4

Death Receptor-4

GFP

green fluorescent protein

LNA

locked nucleic acid

MCM7

minichromosome maintenance protein-7

qRT-PCR

quantitative reverse transcription polymerase chain reaction

SAM

significance analysis of microarray

SEM

standard error of the mean

TRAIL

TNF-related apoptosis inducing ligand

UTR

untranslated region
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Figure 1. mir-106b~25 Expression is Supported by Hedgehog Signaling
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Quantitation of mir-106b~25 expression in cholangiocarcinoma cells (KMCH) by qRTPCR
of total RNA isolated from cell lysates after 24 hr treatment with vehicle, sonic Hedgehog
(500 nM), or cyclopamine (5 ȝM). Expression of studied microRNAs was normalized to
RNU-U6 expression (delta-delta Ct). Mean +/- SEM, n = 3, miR-106b and miR-25
expressions were statistically different based on SAM analysis of Hedgehog versus
cyclopamine treatment groups, with a false discovery rate of zero.
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Figure 2. Increased Expression of mir-106b~25 in Cholangiocarcinoma Cell Lines and Human
Tumor Samples
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Panel A: miR-106b expression was measured by qRT-PCT from total RNA isolated from
lysates of the indicated cell lines. Results are presented as relative expression using Z30 as
an internal control and employing the delta-delta Ct method (mean +/- SEM; n = 3; *p <
0.05, **p < 0.01). Panel B: miR-93 expression from indicated cell lines, presented as above
(***p<0.001). Panel C: miR-25 expression from the indicated cell lines, presented as above.
Panel D: Similarly, miR-106b was measured by qRT-PCR of total RNA isolated from
frozen human tumor samples. Relative expression was determined (delta-delta Ct) compared
to Z30 (internal control) and results are presented as fold change (log2) compared to the
average expression measured in four non-malignant human liver samples, and sorted based
on expression. Sample numbers indicate the patients from which each was obtained. Panel
E: miR-93 expression from human tumor cells, presented as above. Panel F: miR-25
expression from human tumors, presented as above.
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Figure 3. MCM7 mRNA Expression is Increased in Cholangiocarcinoma Cell Lines and Human
Samples with High Expression of miR-25

Panel A: Quantitation by qRT-PCR of MCM7 mRNA in whole cell lysates from nonmalignant H69 cells compared to malignant KMCH and Mz-ChA-1 cells. Relative
expression was determined (delta-delta Ct) compared to 18S (internal control), mean +/SEM; n = 3; *p < 0.05. Panel B: MCM7 mRNA levels were similarly quantified and
analyzed in human cholangiocarcinoma samples comparing groups with high versus low
miR-25 expression.
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Figure 4. miR-25 Protects Cells from TRAIL-induced Apoptosis

Panel A: Non-malignant H69 cells were transfected with control RNA or mir-25 precursor
as indicated to induce miR-25 overexpression. Eighteen hours after transfection, TRAIL was
added at 4 ng/ml for an additional 6 hours to induce apoptosis. Cell were stained with DAPI
and evaluated based on nuclear morphology for presence of apoptosis. Data are presented as
the percentage of cells with apoptotic nuclear morphology out of total cell count and as
mean of at least three experiments (mean +/-SEM, ***p<0.001). At least 100 cells were
counted in each experiment. Panel B: In parallel, KMCH cells were transfected with control
LNA (CT) or miR-25 antagonistic LNA (LNA-25). Two days after transfection, TRAIL at 4
ng/ml was added where indicated for an additional 6 hours. Cells were analyzed with DAPI
for percent of apoptotic nuclei, as above (mean +/- SEM, **p<0.01).
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Figure 5. Altered miR-25 Reciprocally Affects DR4 Protein Expression
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Panel A: KMCH cells were transfected with mir-25 precursor for 24 hours. Extracted total
RNA was analyzed by qRT-PCR to confirm augmented miR-25 expression. Mean +/- SEM;
n = 3, **p < 0.01. Panel B: KMCH cells were transfected (48 hr) with locked nucleic acid
antagonists to miR-25 (LNA-25), miR-106b (LNA-106b), or control LNA (CT). Total RNA
was then subjected to qRT-PCR for miR-25 (left) or miR-106b (right) as well as Z30
(internal control). Data are presented as relative expression (delta-delta Ct compared to
Z30). Mean +/- SEM; n = 3, *p<0.05, **p<0.01. Panel C: KMCH total lysates were
examined by immunoblot for the indicated polypeptides after cell transfection (24 hr) with
control (CT) or mir-25 precursor. Actin was used as a loading control. Apparent molecular
weight indicated in kilodaltons (kDa). Panel D: Similarly, Mz-ChA-1 or H69 cells were
transfected with control or mir-25 precursor and total cellular protein was analyzed by
immunoblot for DR4 and actin. Panel E: KMCH cells, where indicated, were transfected (48
hr) with control LNA (CT), LNA-25, or LNA 106b as a specificity control. Whole cell
lysates were analyzed for the indicated polypeptides by immunoblot. Panel F: Total cellular
protein was isolated from H69, KMCH, and Mz-ChA-1 cells and analyzed for DR4 protein
by immunoblot with actin as a loading control.

Hepatology. Author manuscript; available in PMC 2013 February 1.

Razumilava et al.

Page 16

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 6. DR4 Repression by miR-25 and Functional Rescue Via miR-25-resistant DR4

Panel A: After transfection of KMCH cells with control locked nucleic acid (CT) or LNA
against miR-25 (LNA-25) for 48 hours, slides were prepared and analyzed by confocal
microscopy for immunofluorescence intensity of DR4 or DR5. Panel B: Fluorescence
intensity of cells transfected and stained as in panel A was quantified by ImageJ software.
The data are presented as fold change in the average DR4 or DR5 intensity, mean +/-SEM,
***p<0.001. Panel C: H69 cells were transfected (24hr) with control (CT) or mir-25
precursor; slides were prepared and examined for DR4 immunofluorescence by confocal
microscopy. Panel D: DR4 fluorescence intensity in H69 cells was quantified by ImageJ
software and presented as fold change in average signal intensity between control and
treatment groups, mean +/- SEM, ***p<0.001. Panel E: H69 cells were transfected with
GFP plus pCDNA, GFP plus pCDNA-mir-25, or DR4-GFP plus pCDNA-mir-25. Eighteen
hours after transfection, TRAIL was added at 4 ng/ml for additional 6 hours to induce
apoptosis. Cells were stained with DAPI and GFP-positive cells were evaluated based on
nuclear morphology for presence of apoptosis. Data are presented as the percentage of cells
with apoptotic nuclear morphology out of total cell count (mean +/-SEM, **p<0.01,
***p<0.001).
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Figure 7. miR-25 Targets the DR4 3'UTR to Mediate Gene Expression

Panel A: Total RNA from H69, KMCH, and Mz-ChA-1 cell lines were analyzed for DR4
mRNA expression by qRT-PCR. Relative expression was determined (delta-delta Ct)
compared to 18S (internal control), mean +/- SEM; n = 3; *p < 0.05. Panel B: Human tumor
samples were grouped based on the level of miR-25 expression (high versus low) and
analyzed for DR4 mRNA expression by qRT-PCR. Data are presented as relative expression
with 18S used as an internal control. Panel C: Schematic presentation of the empty parental
Luciferase reporter (pMir), the luciferase construct containing the full length DR4 3'UTR
(pMirDR4), and a two-base binding site mutant (pMirDR4-25mut). Panel D. KMCH cells
were transiently transfected with pMir, pMirDR4, or pMirDR4-25mut, as indicated. Cells
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were also co-transfected with either empty control vector (pCDNA) or with a miR-25
expression vector (pCDNA-mir-25). Twenty-four hours after transfection, cells were lysed
and luciferase activity measured. The activity was normalized to the total protein content,
and expressed as fold change relative to the corresponding pCDNA value (set at 1.0), mean
+/- SEM. ** p < 0.01; n.s. = not significant.
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Figure 8. Regulation of Apoptosis by miR-25 Overexpression

Schematic diagram illustrating the role of miR-25 in cholangiocarcinoma TRAIL deathreceptor signaling. Panel A. Increased miR-25 expression, driven in part by Hedgehog
signaling, targets DR4 for repression which results in TRAIL resistance in tumor cells,
permitting cell survival. Panel B. Antagonism of miR-25 via LNA-25 permits elevated DR4
protein levels, and thus increased tumor cell death.
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Table 1

Cyclopamine suppression of microRNA expression
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Inhibition of Hedgehog signaling (cyclopamine 5 ȝM for 24 hours) caused a reduction in microRNA
expression for 14 microRNAs compared to cells treated with recombinant human Sonic Hedgehog. Data are
presented as the percent reduction of the microRNA signal compared to Hedgehog-treated cells, such that no
reduction would be reported as 0% and complete elimination would be 100% reduction. Only microRNAs
with significant alteration (significance analysis of microarrays) are listed.
Gene Name

Reduction (%)

let-7g

74.27

let-7i

64.96
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miR-15b

52.44

miR-22

54.28

miR-24

64.00

miR-25

76.43

miR-29c

55.98

miR-99a

34.93

miR-103

51.82

miR-106b

59.99

miR-125a-5p

51.32

miR-181b

41.71

miR-186

54.18

miR-191

39.47
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